Nausea News and Research RSS Feed - Nausea News and Research

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.
CDC identifies six new cases of people with Heartland virus

CDC identifies six new cases of people with Heartland virus

The Centers for Disease Control and Prevention in collaboration with health officials in Missouri and Tennessee have identified six new cases of people sick with Heartland virus: five in Missouri and one in Tennessee. The new cases, discovered in 2012 and 2013, are described today in CDC's Morbidity and Mortality Weekly Report. [More]
Study develops new cancer drug that can manipulate the body's natural signalling, energy systems

Study develops new cancer drug that can manipulate the body's natural signalling, energy systems

A revolution in cancer treatment could soon be underway following a breakthrough that may lead to a dramatic improvement in cancer survival rates. [More]
European Commission approves Exelixis' COMETRIQ for treatment of progressive, metastatic MTC

European Commission approves Exelixis' COMETRIQ for treatment of progressive, metastatic MTC

Exelixis, Inc. today announced that the European Commission has approved COMETRIQ (cabozantinib) for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC). [More]
FDA approves Xolair for treatment of chronic idiopathic urticaria

FDA approves Xolair for treatment of chronic idiopathic urticaria

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria, a form of chronic hives. [More]

ZL105 drug could potentially replace currently used anticancer drugs, study finds

A revolution in cancer treatment could soon be underway following a breakthrough that may lead to a dramatic improvement in cancer survival rates. [More]
Sea lions exposed to toxin in algae develop form of epilepsy that is similar to humans

Sea lions exposed to toxin in algae develop form of epilepsy that is similar to humans

California sea lions exposed to a toxin in algae develop a form of epilepsy that is similar to one in humans, according to a new study led by Stanford University School of Medicine researchers. [More]

Medivir announces phase III ATTAIN study of simeprevir inhibitor in treatment of adult patients with HCV

Medivir AB today announced that new phase III data for the once-daily protease inhibitor simeprevir have been presented at the Conference of the Asian Pacific Association for the Study of the Liver (APASL) in Brisbane, Australia. [More]

Study of high school players find no link between years of play and decline in neurocognitive function

As more parents consider whether it's safe for adolescents to play football, a new Tulane University study of high school players found no link between years of play and any decline in neurocognitive function. [More]
Merck's NOXAFIL injection gets FDA approval for intravenous use

Merck's NOXAFIL injection gets FDA approval for intravenous use

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL (posaconazole) injection (18 mg/ mL), a new formulation of NOXAFIL for intravenous (IV) use. [More]
Study finds no link between neurocognitive function and years of football play in adolescent athletes

Study finds no link between neurocognitive function and years of football play in adolescent athletes

A new study presented today at the 2014 Annual Meeting of the American Academy of Orthopaedic Surgeons found no link between neurocognitive function and years of football play in adolescent athletes. [More]
Investigators urge drug regulators to provide clear evidence on statins’ side effects

Investigators urge drug regulators to provide clear evidence on statins’ side effects

At a time when the wider prescription of statins is under renewed public scrutiny, a substantial analysis of placebo-controlled randomised trials of statins has found that only a small minority of side effects reported by those taking the cholesterol-lowering drugs are actually attributable to them. [More]
Orexo signs multi-year agreement with OptumRx and UnitedHealth Group

Orexo signs multi-year agreement with OptumRx and UnitedHealth Group

Orexo AB, the manufacturer of ZUBSOLV® (buprenorphine and naloxone) sublingual tablets (CIII), announced a multi-year agreement with UnitedHealth Group® and OptumRx® providing preferred coverage and reimbursement of ZUBSOLV®. [More]
Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma (HCC), or liver cancer, who had no detectable disease after surgical resection or local ablation, did not meet its primary endpoint of improving recurrence-free survival. [More]
Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma, Inc. today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. [More]
New research reveals how substance abuse problems take hold in returning veterans

New research reveals how substance abuse problems take hold in returning veterans

Of nearly 1 million veterans who receive opioids to treat painful conditions, more than half continue to consume opioids chronically or beyond 90 days, new research says. Results presented at the 30th Annual Meeting of the American Academy of Pain Medicine reported on a number of factors associated with opioid discontinuation with the goal of understanding how abuse problems take hold in returning veterans. [More]
Incyte Corporation publishes results of Phase III trial of ruxolitinib in patients with polycythemia vera

Incyte Corporation publishes results of Phase III trial of ruxolitinib in patients with polycythemia vera

Incyte Corporation (Nasdaq: INCY) today announced that a pivotal Phase III trial of ruxolitinib compared to best available therapy in patients with polycythemia vera who are resistant to or intolerant of hydroxyurea has met its primary endpoint of achieving phlebotomy independence and reducing spleen size by 35 percent or more. [More]

Consumption of energy drinks may be linked with poor mental health, substance use among teens

The uplifting effects of energy drinks are well advertised, but a new report finds consumption among teenagers may be linked with poor mental health and substance use. [More]

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Today Boehringer Ingelheim announced results from STARTVerso4 in patients with HCV/HIV co-infection. Hepatitis C viral cure 12 weeks after the conclusion of treatment (SVR12) was achieved by 72% of all patients in the trial. Patients were enrolled in either 120mg or 240mg faldaprevir dose groups. [More]
Metallic toys, low-cost jewelry can affect children's health

Metallic toys, low-cost jewelry can affect children's health

We know that babies and young children often put non-food items in their mouths, a behaviour that occasionally leads to swallowing of foreign objects. Metallic toys and low-cost jewelry often contain toxic substances such as lead and cadmium. [More]

Loyola surgeon successfully performs operation on patient suffering from rare disorder

Jarely Sanchez is an affectionate, energetic little girl who loves ballet. "Everyone she meets, she connects with," said her father, Jose Angel Ulloa. "She's like a magnet." But for more than a week, the three-year-old girl wasn't herself. [More]